Trexquant Investment’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Trexquant Investment’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-40,552	Closed	-$228K	–	1843
2021 Q4	$228K	Buy	40,552 +25,919	+177%	+$165K	0.01%	1076
2021 Q3	$94K	Buy	+14,633	New	+$94K	0.01%	1056
2021 Q2	–	Sell	-21,361	Closed	-$224K	–	1622
2021 Q1	$224K	Buy	+21,361	New	+$301K	0.02%	918
2020 Q4	–	Sell	-15,104	Closed	-$194K	–	1615
2020 Q3	$194K	Buy	+15,104	New	+$191K	0.01%	1087
2020 Q2	–	Sell	-26,610	Closed	-$245K	–	1569
2020 Q1	$245K	Buy	+26,610	New	+$343K	0.02%	917

Other funds holding PRVB

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Trexquant Investment's PRVB Position: Q1 2022 in Review

Trexquant Investment sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2022, closing a stake of 40,552 shares — an estimated $228K sold.

Trexquant Investment first reported a position in PRVB in Q1 2020 and held it in 5 quarters. The position peaked at $245K in Q1 2020. 113 funds tracked by Wall St. Rank hold PRVB as of Q1 2022.

Trexquant Investment reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Trexquant Investment sold 40,552 Provention Bio, Inc. Common Stock shares in Q1 2022, an estimated $228K.
Trexquant Investment first reported a position in Provention Bio, Inc. Common Stock in Q1 2020 and held it in 5 quarters.
Trexquant Investment's Provention Bio, Inc. Common Stock position peaked at $245K in Q1 2020.
113 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2022.

Based on Trexquant Investment's 13F filing for Q1 2022, filed 13 May 2022.